<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/22/aduro-biotech-inc-nasdaqadro-expected-to-announce-earnings-of-0-21-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-22T18:46:41+00:00"/>
    <meta property="og:title" content="Aduro BioTech Inc (NASDAQ:ADRO) Expected to Announce Earnings of -$0.21 Per Share"/>
    <meta property="og:description" content="Wall Street brokerages forecast that Aduro BioTech Inc (NASDAQ:ADRO) will post earnings per share of ($0.21) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Aduro BioTech’s earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.23). Aduro BioTech reported earnings per […]"/>
  </head>
  <body>
    <article>
      <h1>Aduro BioTech Inc (NASDAQ:ADRO) Expected to Announce Earnings of -$0.21 Per Share</h1>
      <address><time datetime="2019-11-22T18:46:41+00:00">22 Nov 2019, 18:46</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/aduro-biotech-inc-logo.png"/>
      </figure>
      <p>Wall Street brokerages forecast that Aduro BioTech Inc (NASDAQ:ADRO) will post earnings per share of ($0.21) for the current fiscal quarter, according to <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks</a>. Four analysts have made estimates for Aduro BioTech’s earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.23). Aduro BioTech reported earnings per share of ($0.28) in the same quarter last year, which would indicate a positive year over year growth rate of 25%. The company is expected to announce its next quarterly earnings report on Wednesday, February 26th.</p>
      <p>According to Zacks, analysts expect that Aduro BioTech will report full-year earnings of ($0.99) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.89). For the next year, analysts expect that the business will post earnings of ($0.79) per share, with EPS estimates ranging from ($1.02) to ($0.41). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Aduro BioTech.</p>
      <p>Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. Aduro BioTech had a negative return on equity of 78.64% and a negative net margin of 544.94%. The company had revenue of $4.80 million for the quarter, compared to analyst estimates of $4.55 million.</p>
      <p>Several brokerages have weighed in on ADRO. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=ADRO">ValuEngine</a> raised Aduro BioTech from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Cowen reaffirmed a “buy” rating on shares of Aduro BioTech in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $6.68.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/ADRO/earnings/">ADRO stock</a> traded up $0.01 during mid-day trading on Friday, hitting $1.07. The stock had a trading volume of 7,098 shares, compared to its average volume of 843,558. The company has a current ratio of 7.26, a quick ratio of 7.26 and a debt-to-equity ratio of 0.39. Aduro BioTech has a 1-year low of $0.90 and a 1-year high of $4.59. The company has a fifty day moving average of $1.05 and a 200 day moving average of $1.63. The stock has a market capitalization of $88.57 million, a price-to-earnings ratio of -0.92 and a beta of 1.48.</p>
      <p>In other news, CEO Stephen T. Isaacs sold 31,098 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $1.31, for a total transaction of $40,738.38. Following the transaction, the chief executive officer now owns 295,926 shares of the company’s stock, valued at approximately $387,663.06. The sale was disclosed in a legal filing with the SEC, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/1193201/000156761919018457/xslF345X03/doc1.xml">this hyperlink</a>. In the last three months, insiders have sold 52,185 shares of company stock worth $68,362. 5.20% of the stock is currently owned by insiders.</p>
      <p>Hedge funds and other institutional investors have recently modified their holdings of the company. Wedbush Securities Inc. acquired a new stake in Aduro BioTech in the 3rd quarter valued at approximately $39,000. UBS Asset Management Americas Inc. grew its holdings in Aduro BioTech by 106.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 55,233 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 28,533 shares during the last quarter. Jane Street Group LLC acquired a new stake in Aduro BioTech in the 2nd quarter valued at approximately $56,000. Morgan Stanley grew its holdings in Aduro BioTech by 138.8% in the 2nd quarter. Morgan Stanley now owns 66,730 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 38,782 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in Aduro BioTech by 75.8% in the 2nd quarter. AQR Capital Management LLC now owns 701,608 shares of the biotechnology company’s stock valued at $1,080,000 after buying an additional 302,573 shares during the last quarter. 41.24% of the stock is currently owned by institutional investors and hedge funds.</p>
      <p>
        <b>About Aduro BioTech</b>
      </p>
      <p>Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.</p>
      <p>Read More: <a href="https://www.marketbeat.com/market-data/most-active-stocks/">What causes a stock to be most active?</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=ADRO">Get a free copy of the Zacks research report on Aduro BioTech (ADRO)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ADRO"/>
      </figure>
    </article>
  </body>
</html>